clinical trial · NCT04760769
Open-label Trial in Parkinson's Disease (PD)
AbbVie·phase3·completed·n = 992
Parkinson DiseaseTavapadon
brief summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
started
Feb 24, 2021
primary completion
Dec 1, 2025
completion
Dec 1, 2025
last updated
Dec 23, 2025
official title
58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol